BIOSPLICE THERAPEUTICS
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
BIOSPLICE THERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2008-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.biosplice.com
Total Employee:
51+
Status:
Active
Contact:
8589529303
Total Funding:
778 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content US Privacy User Signal Mechanism ASP.NET Google Analytics 4
Similar Organizations
Aspect Biosystems
Biotech company developing bioprinted tissue therapeutics to transform how we treat disease.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
EvolveImmune Therapeutics
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies.
Hopewell Therapeutics
Hopewell Therapeutics is a Synthetic Lipid-based drug delivery company for gene therapy and gene editing.
Lycia Therapeutics
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Nectin Therapeutics
Nectin Therapeutics is a startup company dedicated to the development of next generation immuno-oncology antibodies.
PhenoVista Biosciences
PhenoVista Biosciences provides high content imaging-based phenotypic assay development and screening services.
Rondo Therapeutics
Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Spartan Bioscience
Spartan Bioscience designs and manufactures sample-to-result DNA testing systems.
Twist Bioscience
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Board_member
2021-04-15
Board_member
2021-04-15
Current Employees Featured
Osman Kibar CEO & Founder @ Biosplice Therapeutics
CEO & Founder
2008-01-01
Cevdet Samikoglu President & Chief Financial Officer @ Biosplice Therapeutics
President & Chief Financial Officer
2019-12-01
Yusuf Yazici Chief Medical Officer @ Biosplice Therapeutics
Chief Medical Officer
2013-01-01
Arman Oruc Chief Legal Officer @ Biosplice Therapeutics
Chief Legal Officer
Neil Bair Vice President / Market Access @ Biosplice Therapeutics
Vice President / Market Access
2016-09-01
Blake Mobley Chief Information Officer @ Biosplice Therapeutics
Chief Information Officer
2013-01-01
Erich Horsley Chief Business Officer @ Biosplice Therapeutics
Chief Business Officer
Mark Fineman SVP, Clinical Development @ Biosplice Therapeutics
SVP, Clinical Development
2018-12-01
Founder
Investors List
Sands Capital Ventures
Sands Capital Ventures investment in Venture Round - Biosplice Therapeutics
Verition Fund Management
Verition Fund Management investment in Venture Round - Biosplice Therapeutics
Eventide
Eventide investment in Venture Round - Biosplice Therapeutics
aMoon Fund
aMoon Fund investment in Venture Round - Biosplice Therapeutics
Symbiosis Group
Symbiosis Group investment in Venture Round - Biosplice Therapeutics
Cem OrtabaÅŸ
Cem OrtabaÅŸ investment in Series C - Biosplice Therapeutics
Starling Group
Starling Group investment in Series B - Biosplice Therapeutics
Vickers Venture Partners
Vickers Venture Partners investment in Series B - Biosplice Therapeutics
Swicorp
Swicorp investment in Series B - Biosplice Therapeutics
Polar Light Ventures
Polar Light Ventures investment in Series A - Biosplice Therapeutics
Official Site Inspections
http://www.biosplice.com Semrush global rank: 3.53 M Semrush visits lastest month: 4.19 K
- Host name: 40.118.101.67
- IP address: 40.118.101.67
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Biosplice Therapeutics"
Biosplice Therapeutics - Wikipedia
Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California. [1] It was founded in 2008 by Osman Kibar. [2]Samumed's …See details»
Biosplice Therapeutics - Crunchbase Company Profile & Funding
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop …See details»
Biosplice Therapeutics - 2025 Company Profile - Tracxn
Mar 12, 2025 Biosplice Therapeutics. has raised a total funding of $778M over 3 rounds. Its first funding round was on Sep 2013. What are the most recent funding rounds of Biosplice …See details»
News - Biosplice
Apr 15, 2021 Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance its Alternative Splicing Platform: 2020. Date Title; Dec 01 Darrin M. Beaupre, M.D., Ph.D. joins …See details»
Biosplice Therapeutics - The Org
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop …See details»
Biosplice Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis and cirtuvivint for numerous cancers, with a broad pre-clinical pipeline that encompasses Alzheimer’s disease, …See details»
Pipeline - Biosplice
Biosplice has established clinical proof-of-concept for therapeutic modulation of alternative splicing with the development of lorecivivint, targeting osteoarthritic disease progression by …See details»
Biosplice Therapeutics - Contacts, Employees, Board Members, …
Organization. Biosplice Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Biosplice Therapeutics has 9 current employee profiles, …See details»
Biosplice - Overview, News & Similar companies | ZoomInfo.com
Dec 14, 2022 Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial Robust two-year X-ray results of medial joint space width …See details»
Biosplice Therapeutics - Facebook
Biosplice Therapeutics. 1,092 likes · 1 talking about this. Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.See details»
Mirta Grifman - Biosplice Therapeutics - LinkedIn
Biosplice Therapeutics San Diego, California, United States ... His main mission was to amplify the CEO’s impact within the organization by boosting the performance of the leadership team, …See details»
Cevdet Samikoglu - Chief Executive Officer @ Biosplice …
Cevdet Samikoglu is a Chief Executive Officer at Biosplice Therapeutics. He attended Harvard Business School. New. Resources. Advanced Search. Start Free Trial ... CB Rank (Investor) …See details»
Discovery and Preclinical Development of SM15685, a Novel …
Jan 9, 2025 Corresponding Author. Chi-Ching Mak [email protected] Biosplice Therapeutics, Inc., San Diego, CA, USA. Correspondence. Chi-Ching Mak, Biosplice Therapeutics, Inc ...See details»
Osteoarthritis - Biosplice
Biosplice Therapeutics is proud to be a Corporate Member of OARSI, the leading medical society for advancing the understanding, early detection, treatment, and prevention of osteoarthritis …See details»
Biosplice to Present Positive Lorecivivint Phase 3 Data for Knee ...
Jun 3, 2024 Biosplice's focus on the study of CLKs and DYRKs, which are involved in cell cycle regulation, splicing, and neurodevelopment, positions the company at the forefront of research …See details»
Biosplice Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...
May 29, 2023 Explore Biosplice Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 23 clinical trials, 17 news, and 1 literature.See details»
Biosplice announces Interim data from phase 3 long-term …
Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company, announced potential structure-modifying highlights from an ongoing long-term extension study, OA-07, for …See details»
Privacy Policy - Biosplice
If you do not want us to share your personal information with Biosplice Affiliates for marketing purposes, you may opt-out of such uses by notifying us in accordance with the procedure set …See details»
Simplification for success: Rewiring the biopharma operating …
2 days ago Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
Lorecivivint (SM04690), an Intra-articular, Small-Molecule
•All authors are current or former employees of Biosplice Therapeutics, Inc. or its affiliates. 2. Background •Osteoarthritis (OA) is characterized by increased cartilage thinning, bone …See details»